A first-in-human (FIH), multicentre, open-label, Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of YH004 as a single agent and YH004 in combination with Toripalimab (Anti-PD-1 mAb) in subjects with advanced solid tumors and relapsed or refractory non-hodgkin lymphoma

  • Hamid, Anis (Primary Chief Investigator (PCI))
  • Lai, Li Hoon (Project Manager)

Project: Research

Project Details

Effective start/end date13/10/2131/12/24


  • Solid tumours
  • Non-hodgkin lymphoma
  • Blood cancer
  • Clinical trial